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Background: Understanding trends in the incidence and outcomes of myocardial infarction and stroke, and
how these are influenced by changes in cardiovascular risk factors can inform health policy and healthcare
provision.
Methods: We identified all patients 30 years or older with myocardial infarction or stroke in Scotland. Risk
factor levels were determined from national health surveys. Incidence, potential impact fractions and burden
attributable to risk factor changes were calculated. Risk of subsequent fatal and non-fatal events (myocardial
infarction, stroke, bleeding and heart failure hospitalization) were calculated with multi-state models.
Findings: From 1990 to 2014, there were 372,873 (71§13 years) myocardial infarctions and 290,927 (74§13
years) ischemic or hemorrhagic strokes. Age-standardized incidence per 100,000 fell from 1,069 (95% confi-
dence interval, 1,024-1,116) to 276 (263-290) for myocardial infarction and from 608 (581-636) to 188 (178-
197) for ischemic stroke. Systolic blood pressure, smoking and cholesterol decreased, but body-mass index
increased, and diabetes prevalence doubled. Changes in risk factors accounted for a 74% (57-91%) reduction
in myocardial infarction and 68% (55-83%) reduction in ischemic stroke. Following myocardial infarction, the
risk of death decreased (30% to 20%), but non-fatal events increased (20% to 24%) whereas the risk of both
death (47% to 34%) and non-fatal events (22% to 17%) decreased following stroke.
Interpretation: Over the last 25 years, substantial reductions in myocardial infarction and ischemic stroke
incidence are attributable to major shifts in risk factor levels. Deaths following the index event decreased for
both myocardial infarction and stroke, but rates remained substantially higher for stroke.
Funding: British heart foundation
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)249,Department of Non-com-
giene and Tropical Medicine,
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Planning of healthcare provision for acute cardiovascular disease
requires an understanding of population trends in both the incidence
and subsequent clinical outcomes following acute presentation.Insights into how these trends have been impacted by changes in risk
factor profiles over time are needed to inform public health policy.
Despite considerable overlap between myocardial infarction and
stroke, with shared pathophysiological mechanisms, risk factors and
management, they have rarely been studied concurrently.[1] Previ-
ous studies comparing incidence for these two conditions were not
contemporary.[1-3] Those reporting trends for myocardial infarction
have predominantly been limited to fatal events,[4-9]whilst stroke
studies have been limited to smaller cohorts and younger popula-
tions.[10,11-13] Whilst the associations between risk factors and
Research in Context
Evidence before this study: We searched Ovid Medline (from
01/01/1995 to 01/08/2020) for search terms ‘cardiovascular
risk factors’, ‘incidence’, ‘myocardial infarction’, ‘stroke’ and
‘outcomes’. We identified several studies including systematic
reviews evaluating trends in incident myocardial infarction or
stroke. Several studies evaluated impact of changes in risk fac-
tors on coronary death. We found no large contemporary
nationwide studies comparing the clinical burden of stroke and
myocardial infarction, evaluating the impact of population
changes in risk factors on fatal and non-fatal disease and the
short- and longer-term fatal and non-fatal clinical sequalae fol-
lowing index event.
Added value of this study: In a large contemporary nation-
wide patient level linkage study we show that substantial
reductions in myocardial infarction and ischemic stroke inci-
dence are associated with reductions in systolic blood pressure,
smoking and cholesterol but attenuated by increases in body
mass index and diabetes prevalence. Importantly, we now
show that in addition to the incidence of both myocardial
infarction and stroke declining, the temporal difference in the
incidence has also narrowed. Deaths following the index event
decreased for both myocardial infarction and stroke, but rates
remained substantially higher for stroke. The clinical burden of
stroke, both in terms of incidence and case-fatality, now con-
tributes to a greater burden of acute cardiovascular disease.
Implications of all the available evidence: Substantial reduc-
tions in the incidence of both myocardial infarction and ische-
mic stroke can be achieved by addressing biological and
behavioural risk factors. These observations have major impli-
cations for countries in low- and middle-income settings where
rates of hypertension and dyslipidaemia are rising as well as
the residual risk from persistent uncontrolled risk factors in
high-income countries. We also highlight the increasing influ-
ence of obesity and diabetes on acute cardiovascular events,
which have implications for all countries given that both risk
factors are rising worldwide. Finally, differences in the burden
of myocardial infarction and stroke are narrowing, particularly
in women, and monitoring these trends is essential for the
planning of healthcare provision in the decades that follow.
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impact of temporal changes in risk factors on the incidence of both,
and in those with and without fatal presentations, remains uncertain.
The last two decades has seen substantial changes in the manage-
ment and outcomes of myocardial infarction and stroke.[12,17-23]
Most studies have reported trends in morbidity and mortality during
the acute phase,[13,24,25] with studies of the longer term sequelae
scarce[26] and report inconsistent findings.[27-31]
Reliable information about the comparative epidemiology regard-
ing clinical burden, risk factor impact and the subsequent sequelae
following myocardial infarction and stroke remains scarce. To inform
public health policy and healthcare provision, we investigated the
impact of population changes in risk factors over 25 years on incident
myocardial infarction and stroke. We also report on changes in risk of
subsequent fatal events, and single and multiple non-fatal events fol-
lowing index non-fatal myocardial infarction or stroke.2. Methods
2.1. Study population, design and data sources
An individual patient-level linkage study (Supplement figure 1)
using national datasets in Scotland (Supplementary text 1) includedPlease cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Eall patients 30 yearsof age or older with myocardial infarction or
stroke from January 1st, 1990 to December 21st, 2014 with follow-up
until December 31st, 2017. Using a 5-year lookback period (Supple-
mentary text 2), index cases were identified as ICD-10 coded hospi-
talisations or deaths without prior hospitalisation(Supplementary
table 1).Age at incident event, sex, comorbidity and area-based mea-
sure of deprivation using the Scottish Index of Multiple Deprivation
(SIMD) were extracted.[32]
All index cases were linked to prior and subsequent hospital epi-
sodes and deaths from the National Health Service (NHS) Scottish
Morbidity Register and National Records of Scotland using theCom-
munity Health Index, a register of all Scottish NHS patients. Age- and
sex-stratified mid-year population estimates were obtained from
National Records of Scotland. Non-fatal events consisted of heart fail-
ure, stroke, myocardial infarction and bleeding. Access to the data
was approved by the NHS Scotland Public Benefit and Privacy Panel
for Health and Social Care.
Age-, sex- and year-stratified population distribution of cardio-
vascular risk factors (systolic blood pressure, total cholesterol, body
mass index and the prevalence of smoking and diabetes mellitus)
were estimated from the Scottish Health Survey.[33] The Scottish
Health Survey uses a multistage stratified clustered probability sam-
pling design to ensure the results are representative of the popula-
tion (Supplementary text 3). The surveys were conducted in 1995,
1998, 2003 and then annually from 2008. Age- and sex-stratified risk
ratios for each risk factor were extracted from the published litera-
ture.[14-16,34]2.2. Statistical analysis
Baseline characteristics were summarised in 5-year intervals by
index event.
Incidence modelling: Generalized additive models were used to
estimate trends in incident myocardial infarction and stroke. Annual
incident hospitalisations were aggregated by 10-year age intervals
and sex separately for index myocardial infarction and stroke. Per-
son-time, using the same covariates, was calculated using the popula-
tion mid-year estimates (Supplementary text 2). For incidence rates,
a log link and Poisson error distribution were used with a scaling fac-
tor (quasi-Poisson) to allow for overdispersion. Annual incidence
rates were standardized to the European Standard Population.[35]
Burden: For each risk factor, regression models were constructed
from baseline health survey data to estimate age-, sex- and year-
stratified values (Supplement text 4). The number of events pre-
vented, delayed or caused as a result of a change in risk factor level
was estimated using data from three sources: the age-, sex- and
year-stratified incident count, the age- and sex-stratified (where
available) relative risk and absolute change in age- and sex-stratified
risk factor level. Distributions were combined via Monte Carlo sam-
pling to produce estimates of the potential impact fraction[36] (a
measure of the proportional reduction in the disease or mortality
risk, when the risk factor distributions change) and a final count dis-
tribution for each age-, sex- and year-strata of events prevented,
delayed or caused by change in risk factor levels(Supplementary
text 5).
Multistate outcome models: Time to subsequent fatal and non-fatal
events (3-year follow-up) was modelled using multi-state models for
index non-fatal myocardial infarction and stroke. Weibull accelerated
failure time models were fitted, adjusting for age, sex, deprivation,
cohort period and comorbidity (Supplementary text 6). Estimated
risks were presented at the population level stratified by cohort
period and standardized using the count data of the remaining cate-
gorical variables (sex, deprivation and comorbidity) as well as by age,
sex, deprivation, comorbidity and cohort period. Statistical analyses
were performed in R version 3.5.1 (Vienna, Austria).pact and outcomes following myocardial infarction and stroke: A 25-
urope (2021), https://doi.org/10.1016/j.lanepe.2021.100141
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collection, data analysis, interpretation or writing of the report3. Results
From 1990 to 2014, among 605,996 patients, there were 372,873
(71§13 years, 43% female) and 290,927 (74§13 years, 55% female)
index myocardial infarctions and strokes respectively. Compared to
stroke, patients with myocardial infarction were younger and more
likely to be male.Across the cohort periods, there was a modest nar-
rowing in social inequalities (Table 1, Supplementary table 2 and 3).
3.1. Incidence of myocardial infarction and stroke
Age-standardized incidence per 100,000 fell from 1,069 [95% con-
fidence interval 1,024 to 1,116] to 276 [263 to 290] for myocardial
infarction, and from 608 [581 to 636] to 188 [178 to 197] for ischemic
stroke but remained unchanged (44 [43 to 45] to 44[44 to 45]) for
hemorrhagic stroke (Supplementary table 4). Similar trends were
observed in males and females (Figure 1)with the highest reductions
observed in older age groups (Supplementary figure 2).3.2. Changes in risk factors, potential impact fraction and burden
Over the 25 years, age- and sex-standardized risk factor levels
reduced for systolic blood pressure (140 [139 to 140] to 129 [129 to
130] mmHg), smoking prevalence (58 [54 to 63] to 25 [24 to 26] %)
and cholesterol concentrations (6.4 [6.2 to 6.6] to 5.1 [5.0 to 5.3]
mmol/L). Body mass index (27.2 [27.0 to 27.4) to 28.1 [28.0 to 28.2]
kg/m2) and diabetes prevalence (4 [3 to 5] to 9 [8 to 9] %) increased.
The trends remained consistent across the majority of age and sex
strata(Supplementary figure3). Changes in risk factor prevalence
accounted for a 74 [57-91] % and 68 [55-83] % age- and sex-standard-
ized reduction in myocardial infarction and ischemic stroke. This was
predominantly driven by reduction in systolic blood pressure for
ischemic stroke and in cholesterol and smoking rates for myocardialTable 1.
Baseline characteristics in patients with index fatal and non-fatal myocardia
Variable Index Condition 1990 to 1994
Number Myocardial infarction 100,929
Stroke 64,870
Age, years (mean [SD]) Myocardial infarction 70.2 (12.2)
Stroke 74.0 (12.2)
Sex, females(%) Myocardial infarction 44,435 (44.0)
Stroke 37,149 (57.3)
Past medical history
Ischemic heart disease (%) Myocardial infarction 10,069 (10.0)
Stroke 6,462 (10.0)
Cerebrovascular disease (%) Myocardial infarction 4,934 (4.9)
Stroke 4,422 (6.8)
Heart failure (%) Myocardial infarction 6,507 (6.4)
Stroke 3,717 (5.7)
Coronary revascularisation (%) Myocardial infarction 619 (0.6)
Stroke 372 (0.6)




One (most deprived) Myocardial infarction 27,438 (27.7)
Stroke 17,357 (27.3)
Two Myocardial infarction 24,060 (24.3)
Stroke 15,115 (23.8)
Three Myocardial infarction 19,904 (20.1)
Stroke 12,717 (20.0)
Four Myocardial infarction 15,546 (15.7)
Stroke 10,298 (16.2)
Five (least deprived) Myocardial infarction 12,053 (12.2)
Stroke 8,139 (12.8)
Please cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Einfarction (Figure 2a). In contrast, we observed a 20 [16 to 26] % and
15 [11 to 21] % increase in myocardial infarction and ischemic stroke
incidence attributable to changes in body-mass index and diabetes
prevalence (Supplementary table 5) Differences were observed in
the potential impact fractions according to age and sex. Reductions in
smoking rates and increase in body-mass index had the largest
impact on younger people whilst increases in diabetes prevalence
predominantly impacted the elderly (Supplementary figure 4and
table 6).
Changes in risk factors over 25 years had a larger impact on reduc-
ing burden for incident myocardial infarction (net reduction in events
34,762 [23,412 to 43,727]) than for ischemic stroke (13,247 [9,390 to
16,938])(Figure 2b, Supplementary table 7). For myocardial infarc-
tion, a reduction in smoking rates prevented 9,362 [7,811 to 11,046]
events, but the increase in diabetes prevalence contributed to 7,544
[4,769 to 10,377] additional events.3.3. Outcomes following incident cases
Crude 30-day and 3-year case-fatality rates, including index
deaths, fell for myocardial infarction and ischemic or hemorrhagic
stroke(Table 2) with similar trends observed on restricting analyses
to index non-fatal cases(Supplementary table8).
Following myocardial infarction and stroke, the risk of death with
no interceding event decreased from 30% to 20% and from 47% to 34%
respectively. Risk of any subsequent non-fatal event increased for
myocardial infarction (from 20% to 24%) but decreased for stroke
(from 22% to 17%). Following myocardial infarction, there was an
increase in recurrent myocardial infarction (from 7.7% to 10.6%) and
bleeding (from 2.3% to 4.4%) although heart failure hospitalisations
fell (from 9.1% to 7.1%). Following stroke, the risk of recurrent stroke
was reduced (from 12.3% to 8.2%) and bleeding remained unchanged
(from 4.7% to 4.4%) (Figure 3). Risks following the index event dif-
fered when evaluated by age, sex, deprivation and comorbidity. An
online interactive web application reports the standardized risk of
fatal and non-fatal eventsat 3-years for index myocardial infarctionl infarction or stroke stratified by 5-year calendar groups.
1995 to 1999 2000 to 2004 2005 to 2009 2010 to 2014
82,330 69,415 58,513 61,686
64,593 58,563 52,043 50,858
70.9 (12.5) 71.5 (13.1) 71.3 (13.6) 70.2 (13.9)
74.0 (12.6) 74.0 (13.1) 73.5 (13.5) 73.4 (13.6)
36,220 (44.0) 30,080 (43.3) 24,403 (41.7) 24,559 (39.8)
36,222 (56.1) 32,628 (55.7) 28,155 (54.1) 26,931 (53.0)
10,887 (13.2) 10,381 (15.0) 9,713 (16.6) 9,425 (15.3)
7,274 (11.3) 6,780 (11.6) 6,341 (12.2) 5,961 (11.7)
4,663 (5.7) 3,725 (5.4) 2,856 (4.9) 2,616 (4.2)
4,093 (6.3) 2,727 (4.7) 2,044 (3.9) 1,666 (3.3)
6,445 (7.8) 5,467 (7.9) 4,156 (7.1) 3,663 (5.9)
3,765 (5.8) 3,138 (5.4) 2,482 (4.8) 2,299 (4.5)
818 (1.0) 878 (1.3) 1408 (2.4) 1490 (2.4)
675 (1.0) 828 (1.4) 1154 (2.2) 1391 (2.7)
433 (0.5) 436 (0.6) 458 (0.8) 573 (0.9)
423 (0.7) 418 (0.7) 469 (0.9) 547 (1.1)
21,903 (26.8) 17,959 (26.0) 14,069 (24.2) 15,079 (24.6)
16,833 (26.2) 14,958 (25.7) 12,649 (24.4) 11,988 (23.7)
19,993 (24.5) 16,645 (24.1) 13,585 (23.4) 14,122 (23.1)
15,343 (23.9) 13,738 (23.6) 11,856 (22.9) 11,370 (22.5)
16,455 (20.2) 13,846 (20.1) 11,883 (20.4) 12,278 (20.1)
12,957 (20.2) 11,621 (20.0) 10,514 (20.3) 10,136 (20.1)
12,993 (15.9) 11,307 (16.4) 10,288 (17.7) 10,841 (17.7)
10,470 (16.3) 9,799 (16.8) 9,079 (17.5) 9,099 (18.0)
10,272 (12.6) 9,233 (13.4) 8,326 (14.3) 8,880 (14.5)
8,586 (13.4) 8,121 (13.9) 7,650 (14.8) 7,890 (15.6)
pact and outcomes following myocardial infarction and stroke: A 25-
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Fig. 1. Age standardized incidence rate per 100,000 for myocardial infarction, ischemic stroke and hemorrhagic stroke.
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comorbidity (https://ihwph-hehta.shinyapps.io/614967/).
4. Discussion
There have been substantial changes in the epidemiology of myo-
cardial infarction and stroke over the last 25 years. The incidence of
myocardial infarction and ischemic stroke has reduced 3- to 4-fold
with differences in the age-standardized incidence narrowing for
both men and women. We estimate that over two-thirds of these
reductions can be attributed to major changes in population risk fac-
tors with substantial falls in systolic blood pressure, cholesterolFig. 2a. Stack barplot showing potential impact fraction for myocardial in
Please cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Econcentrations and smoking rates albeit attenuated by increases in
body-mass index and diabetes prevalence. Outcomes following myo-
cardial infarction and stroke have also changed substantially. Death
following the index event has decreased for both myocardial infarc-
tion and stroke, but absolute rates remain high particularly for stroke.
Finally, the risk of subsequent non-fatal clinical events is diverging
with rising recurrent events following myocardial infarction and fall-
ing following stroke.
The trends in myocardial infarction and stroke incidence reported
here are consistent with many previous studies across industrialized
countries over the last three decades. Whilst these prior studies have
predominantly focused on trends in the incidence of coronary deathsfarction and ischemic stroke by risk factor change from 1990 to 2014.
pact and outcomes following myocardial infarction and stroke: A 25-
urope (2021), https://doi.org/10.1016/j.lanepe.2021.100141
Fig. 2b. Stack plot showing absolute number of index myocardial infarction and ischemic stroke events delayed / prevented or caused by change in risk factor level.
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incidence of both fatal and non-fatal myocardial infarction and
stroke. Ford et al observed a 50% reduction in coronary deaths from
1980 to 2000 in the United States.[8] Across a similar time period, the
Oxford Vascular study, with robust case ascertainment, reported a
40% reduction in non-fatal stroke.[37] In our study, the contempora-
neous reductions in fatal and non-fatal myocardial infarction and
ischemic stroke were even greater. Importantly, we now show that
the incidence of both conditions has continued to decline in the
decade that followed and the differences in the incidence narrowing.
Our analysis also showed a trend towards a reduction in social
inequality. The proportion of patients with incident myocardial
infarction and stroke has steadily decreased (from 28% to 25% and
27% to 24% respectively) in the most deprived group and increased
(from 12% to 15% and 13% to 16%) in the least deprived group. Across
the United Kingdom, McCartney et al showed that the most deprived
group experienced the highest absolute reduction in incident coro-
nary mortality but on the relative scale the rate of reductions are
higher for the least deprived groups.[38]
In our study, over two-thirds of the reduction in the incidence of
myocardial infarction and stroke can be attributed to changes in risk
factor prevalence over 25 years. We demonstrated considerable
reductions in systolic blood pressure, cholesterol and smoking, simi-
lar to changes observed in other industrialized countries.[39,40] For
reductions in incident myocardial infarction, changes in systolic
blood pressure, cholesterol and smoking rates contributed equally,
whereas change in systolic blood pressure was the major determi-
nant of the reduction in incident stroke. Increases in the screening
and treatment of hypertension and dyslipidaemia, together with the
use of more potent pharmacotherapies, alongside transformative
public health efforts, such as smoking bans in public places, are likelyPlease cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Eto account for a large part of the reductions observed in our study.
[39,41-44] Whilst smoking rates fell across age groups, the greatest
reductions were observed in younger persons, particularly women.
Smoking increases the risk of myocardial infarction 6-fold in women,
compared to 3-fold in men.[14] Stronger associations coupled with
the greatest temporal reduction, made smoking the single most
important factor associated with the reduction in myocardial infarc-
tionand stroke in young women.
Whilst the majority of risk factor changes have been favorable,
two exceptions are noteworthy and concerning. Increases in body-
mass index and a doubling in the prevalence of diabetes has contrib-
uted considerably to incident myocardial infarction and stroke, atten-
uating the gains observed from better cholesterol and blood pressure
control and reduced smoking rates. In our analysis, body-mass index
increased in younger persons, but was unchanged in the elderly, and
this contributed to an estimated increase in incident stroke and myo-
cardial infarction by a third and quarter respectively. Whilst the prev-
alence of diabetes doubled, increases were more marked in the
elderly, and given the stronger association between diabetes and cor-
onary heart disease, this contributed to a 20% increase in incident
myocardial infarction, with little impact on incident stroke. Overall,
we estimate that across all age groups in the population, the increas-
ing prevalence of diabetes contributed to as many incident myocar-
dial infarctions as were prevented by the reduction in smoking.
Public health efforts now need to urgently focus on managing obesity
and diabetes to further curb cardiovascular disease.[45,46]
In parallel to these major changes in cardiovascular risk factors
and the incidence of myocardial infarction and stroke, our analysis
also demonstrate important changes in morbidity and mortality in
those who survive the index event. Across the 25-year period,the
case-fatality rate declined from approximately 1 in 3 to 1 in 5pact and outcomes following myocardial infarction and stroke: A 25-
urope (2021), https://doi.org/10.1016/j.lanepe.2021.100141
Table 2.
Fatal and non-fatal outcomes in patients with fatal and non-fatal index myocardial infarction and stroke stratified by 5- calendar year groups.
Outcome type Index Condition Outcome time 1990 to 1994 1995 to 1999 2000 to 2004 2005 to 2009 2010 to 2014
Myocardialinfarction Myocardial infarction 30 days 1,333 (1.5) 1,486 (2.1) 1,560 (2.7) 1,501 (3.1) 2,976 (5.5)
One year 4,581 (5.1) 3,892 (5.5) 3,816 (6.6) 3,535 (7.2) 5,550 (10.2)
Three years 7,086 (7.9) 5,453 (7.8) 5,163 (8.9) 4,860 (9.9) 7,337 (13.5)
Stroke 30 days 201 (0.4) 236 (0.4) 188 (0.3) 191 (0.4) 151 (0.3)
One year 920 (1.7) 802 (1.3) 684 (1.2) 645 (1.3) 600 (1.2)
Three years 1,710 (3.2) 1,513 (2.5) 1,268 (2.3) 1,190 (2.4) 1,175 (2.4)
Stroke Myocardial infarction 30 days 76 (0.1) 234 (0.3) 206 (0.4) 199 (0.4) 209 (0.4)
One year 295 (0.3) 791 (1.1) 741 (1.3) 698 (1.4) 780 (1.4)
Three years 699 (0.8) 1,515 (2.2) 1,320 (2.3) 1,254 (2.6) 1,399 (2.6)
Stroke 30 days 928 (1.7) 1,152 (1.9) 1,005 (1.8) 1,037 (2.1) 1,264 (2.6)
One year 5,249 (9.7) 5,214 (8.8) 4,232 (7.7) 3,774 (7.7) 3,453 (7.1)
Three years 7,831 (14.4) 7,618 (12.8) 6,159 (11.2) 5,405 (11.0) 5,048 (10.4)
Heart failure Myocardial infarction 30 days 1,223 (1.4) 1,326 (1.9) 1,301 (2.2) 1,284 (2.6) 1,353 (2.5)
One year 4,895 (5.5) 4,671 (6.7) 4,274 (7.4) 3,479 (7.1) 3,665 (6.8)
Three years 7,267 (8.1) 6,694 (9.5) 5,837 (10.1) 4,847 (9.9) 5,105 (9.4)
Stroke 30 days 200 (0.4) 196 (0.3) 165 (0.3) 160 (0.3) 133 (0.3)
One year 1,206 (2.2) 1,225 (2.1) 978 (1.8) 852 (1.7) 836 (1.7)
Three years 2,337 (4.3) 2,384 (4.0) 1,899 (3.5) 1,659 (3.4) 1,693 (3.5)
Bleeding Myocardial infarction 30 days 142 (0.2) 192 (0.3) 297 (0.5) 443 (0.9) 538 (1.0)
One year 854 (1.0) 897 (1.3) 1,222 (2.1) 1,457 (3.0) 1,804 (3.3)
Three years 1,877 (2.1) 1,916 (2.7) 2,226 (3.8) 2,489 (5.1) 2,997 (5.5)
Stroke 30 days 529 (1.0) 591 (1.0) 585 (1.1) 495 (1.0) 479 (1.0)
One year 2,020 (3.7) 1,775 (3.0) 1,720 (3.1) 1,546 (3.1) 1,466 (3.0)
Three years 3,406 (6.3) 2,981 (5.0) 2,939 (5.4) 2,699 (5.5) 2,620 (5.4)
Death Myocardial infarction 30 days 39,557 (44.1) 27,735 (39.5) 19,711 (34.0) 13,752 (28.0) 10,044 (18.5)
One year 45,899 (51.2) 32,732 (46.6) 24,544 (42.4) 18,204 (37.1) 14,528 (26.8)
Three years 52,106 (58.1) 37,567 (53.5) 28,959 (50.0) 22,229 (45.3) 19,427 (35.9)
Stroke 30 days 15,162 (28.0) 17,961 (30.2) 14,734 (26.9) 11,370 (23.2) 9,341 (19.3)
One year 24,665 (45.5) 26,722 (45.0) 22,784 (41.5) 18,223 (37.1) 15,639 (32.3)
Three years 32,049 (59.1) 33,675 (56.7) 28,986 (52.9) 23,708 (48.3) 21,205 (43.9)
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stroke. Improving survival for both these conditions likely reflects
improvements in secondary prevention[47] and antithrombotic[48]
pharmacotherapy, introduction of acute stroke units,[49] and coro-
nary revascularisation strategies.[50]However, as illustrated in our
online interactive web application, the absolute risks of death across
the population and across age, sex and deprivation strata remain sub-
stantially higher for stroke compared to myocardial infarction. In
addition to the higher case-fatality rate following stroke, there has
been a substantial narrowing in the differences between the inci-
dence of myocardial infarction and stroke since 1990. Indeed, the
incidence rates of myocardial infarction and ischemic stroke are now
identical in women. As a consequence, stroke now contributes to an
increasingly greater burden of acute cardiovascular events and
healthcare provision needs to recognize this.
In contrast to the consistent reductions in case fatality for both
myocardial infarction and stroke, the risk of non-fatal sequelae is
diverging with an increase in recurrent events following myocardial
infarction and a decrease following stroke. Following myocardial
infarction, the risk of recurrent myocardial infarction increased from
8% to 11% likely reflecting changes in the clinical definition,the intro-
duction of more sensitive troponin assays[51,52] and improving sur-
vival from the index event. The observation that subsequent bleeding
rates doubled is likely to be a consequence of the increasing use of
more potent anti-platelet and anti-thrombotic therapies.[53] The risk
of recurrent stroke was reduced without change in bleeding rates,
perhaps suggesting the management of other risk factors is responsi-
ble for improved outcomes.[15]
There are several potential strengths to our study. First, our
approach ensured complete follow-up in those patients who
remained resident in Scotland during the study period. Similar
approaches have been used to deliver randomized clinical trials
[54,55] and cohort studies.[32,56] Second, our population consists of
consecutive patients with myocardial infarction or stroke, avoiding
selection bias and improving generalizability. Third, national admin-
istrative datasets in Scotland have been operational for decades, withPlease cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Emature, high quality and consistent data.[57] Diagnostic coding for
both stroke and ischemic heart disease have been validated against
case note reviews and audit data showing good accuracy.[58-60]
Several limitations need to be highlighted. First, when estimating
the potential impact fraction, we assume that each risk factor is
mutually exclusive.[61] In reality, both myocardial infarction and
stroke occur as a consequence of numerous causal risk factors, rather
than a single cause.[61] As such the estimates in the reduction in inci-
dence for each individual risk factor is likely to be an over-estimate.
Second, we did not consider the effect of lag times between changes
in risk factor levels and incident disease in our analysis. The impact of
smoking cessation is likely to be immediate, whereas the effects of
weight gain and diabetes may not be observed for many years. Third,
the population of Scotland is predominantly white, with small num-
bers of minority ethnic groups thereby precluding stratified analyses
by ethnicity. Fourth, our study predominantly focuses on biological
and behavioural risk factors to the exclusion of social ones. Finally,
other outcomes following myocardial infarction and stroke are
important, such as requirements for social and personal care, and
these are not captured by our administrative data. Further, research
is now needed to evaluate the role social risk factors and its influence
on changes in risk factor levels and subsequent incidence of fatal and
non-fatal cardiovascular disease.
Our findings have implications for public health policy and
healthcare provision. Substantial reductions in the incidence of both
myocardial infarction and ischemic stroke can be achieved by
addressing biological and behavioural risk factors. These observa-
tions have major implications for countries in low- and middle-
income settings where rates of hypertension[39] and dyslipidaemia
[62] are rising as well as the residual risk from persistent uncon-
trolled risk factors in high-income countries. Despite the overall
gains, we also highlight the increasing influence of obesity and dia-
betes on acute cardiovascular events, which have implications for
all countries given that both risk factors are risingworldwide.
[62,63] Finally, differences in the burden of myocardial infarction
and stroke are narrowing, particularly in women, and monitoringpact and outcomes following myocardial infarction and stroke: A 25-
urope (2021), https://doi.org/10.1016/j.lanepe.2021.100141
Fig. 3. Population risks from multistate models  unscaled sunburst plots showing stratum standardized risks for the population for fatal and non-fatal sequalae following index
non-fatal myocardial infarction (A) and stroke (B). Note: A web application has been created (https://ihwph-hehta.shinyapps.io/614967/) to illustrate the predicted risks for up-to three
levels for fatal or non-fatal subsequent events and four levels for subsequent fatal events. The web application also provides conditional probabilities of risks stratified by age, sex, depriva-
tion, presence or absence of comorbidity and cohort period. An adjunct explanatory document has also been submitted to summarize how to use the web-application. On publication, the
web application will be updated with the explanation.
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the decades that follow.
In conclusion, our analysis highlights a considerable decline in
incident myocardial infarction and stroke with over two-thirds of thePlease cite this article as: A.S.V. Shah et al., Clinical burden, risk factor im
year individual patient level linkage study, The Lancet Regional Health - Ereduction attributable to favorable changes in risk factor profiles, but
increasing obesity and diabetes continue to contribute to the clinical
burden.Important changes in the risk of subsequent events following
index stroke and myocardial infarction have occurred. Whilst initialpact and outcomes following myocardial infarction and stroke: A 25-
urope (2021), https://doi.org/10.1016/j.lanepe.2021.100141
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rates remain high.
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